CatalystWireBeta

UK small-cap RNS · 26 Jan 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies
  1. 16:45
    Holding(s) in Company Holding
  2. 16:32
    Unaudited interim results Results
    Interims for a company winding down: revenue fell to £60k from £92k and admin expenses rose to £1,851k from £527k, driven by the loan note settlement; cash fell to £132k.
    Legal & regulatory £1.9m · 380% of mcapfirst in 6 months +0.0% on the day
    Moved: new: Wind-down and search for acquisition – Winding down; actively considering acquisitions · new: FCA-supervised customer asset return – Ongoing wind-down; customer campaigns committed to May 2025
  3. 07:03
    BIA Approval of Irrevocable Letter of Credit
    Quantum Helium Limited (AIM: QHE) is pleased to announce that the Irrevocable Letter of Credit ("ILOC") required for bonding has now been formally approved by the U.S.
    Project milestones outlook positive +0.0% on the day
    Moved: Sagebrush-1 extended flow test: Letter of Credit funded; awaiting BIA review → Letter of Credit approved; assignment and operatorship pending
  4. 07:00
    Conclusion of CDX process & Directorate changes
    Board ends the CDX sale process without firm offers and will instead invest in existing business areas and cut costs. The sale route to value is gone, but the cash is preserved.
    Turnaround plan with targets outlook mixedfirst in 1 year −21.4% on the day
    Moved: Appoint financial adviser and sell trading business (CDX): on_track → changed – The CDX sale process has ended without firm offers, and the Board is no longer actively seeking a buyer. · CDX trading business sale: Talks ongoing with several parties → Sale process ended, no buyer sought (closed) · Shoei non-infringement claim: Shoei filed US declaratory judgement suit → Nanoco has sued Shoei for infringement
  5. 07:00
    Hussar EP513 Drilling/Funding
    Georgina Energy Plc, GEX.L advises Harlequin Energy Ltd ('Harlequin') has formally confirmed its intention to proceed with funding for the Hussar EP513 prospect for the anticipated recovery of Helium, Hydrogen and Natural Gas.
    Project milestones outlook positive +134.6% on the day
    Moved: Hussar well funding: Funding talks ongoing; offtake MOU extended separately → Harlequin formally confirmed funding; JOA governs drilling · Hussar well drilling approvals: Approved; site preparation under way; funding proposed → Approved WMP; drilling programme timetabled for 2026
  6. 07:00
    Successful Diamond Drilling at Bill’s Luck
    Successful diamond resource drilling programme at Bill's Luck Gold Mine
    Project milestones ahead of expectationsoutlook positive +7.7% on the day
    Moved: new: Bill's Luck resource drilling and MRE – Diamond results in; RC results pending · Hillside gold development and plants: Build-out continues under interim leadership → Build-out continues; Bill's Luck 50tpd plant pending
  7. 07:00
    New Pension Scheme Agreement & FY25 Trading Update Trading update
    FY25 adjusted operating profit is in line with consensus, margin should exceed the 4.5% target and net cash of £190m beats the £171m expected, though part of that is working capital timing that unwinds in FY26.
    Capital return £20.0m · 3% of mcapahead of expectationsoutlook positivefirst in 8 months +7.0% on the day
    Moved: new: Enhanced shareholder returns – Board's current intention, not yet confirmed
  8. 07:00
    Trading Update Trading update
    Pro forma revenue grew 11.1% with UK Power Brands up 20.7% after higher A&P spend, and guidance for the 17-month period is reaffirmed. International fell 8.7% on order timing and distributor disruption, which tempers the result.
    Capital return £35.1m · 44% of mcapoutlook positivefirst since Oct 2023 +2.3% on the day
    Moved: new: Earnings-enhancing M&A pursuit – Actively working on several potential targets · new: Share buyback programme – Ongoing; £1.1m returned by 31 December 2025 · new: International partnership restructuring – Spanish office closing; Scandinavia distributor issue resolved
  9. 07:00
    FDA clearance of IND application for iSCIB1+
    Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
    Project milestones outlook positive +1.3% on the day
    Moved: iSCIB1+ melanoma registration path: Regulator feedback aligned; Phase 3 planning, partnering and financing under way → FDA IND cleared; financing/partnering still open

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note